Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Absci Corporation filings document a Nasdaq-listed clinical-stage biotechnology issuer developing generative AI-designed biologic therapeutics. Its 8-K reports furnish quarterly and annual financial results, business presentations, and internal pipeline updates for programs such as ABS-201 and the broader prolactin and PRLR portfolio.
Proxy and material-event filings cover board and shareholder matters, executive compensation and equity-plan governance, director and officer indemnification agreements, common stock registered on the Nasdaq Global Select Market, and amendments to material agreements related to prior corporate transactions.